UPDATE 2-FDA panel backs Acadia drug for psychosis linked to Parkinson's
March 29 (Reuters) - An advisory panel to the U.S. Food and Drug Administration backed an approval for Acadia Pharmaceuticals Inc's drug for psychosis related to Parkinson's disease.
No comments:
Post a Comment